Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Primary Hepatocellular Carcinoma|Adult Subependymoma|Advanced Adult Primary Liver Cancer|Advanced Malignant Mesothelioma|Male Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Malignant Mesothelioma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage II Esophageal Cancer|Stage II Pancreatic Cancer|Stage III Esophageal Cancer|Stage III Pancreatic Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: DRUG: erlotinib hydrochloride|OTHER: laboratory biomarker analysis
Sponsor: National Cancer Institute (NCI)